Skip to main content
. 2018 Jan 19;13(1):e0190751. doi: 10.1371/journal.pone.0190751

Table 3. Patient-reported outcomes at 12-month follow-up in the Embrace study: Overview of the results of the intention-to-treat multilevel analyses for the whole sample and per risk profile.

Whole sample Complex care needs Frail Robust
(n = 1456) (n = 365) (n = 237) (n = 854)
Embrace CAU Embrace CAU Embrace CAU Embrace CAU
Scale scores
(range)
Higher score* Mean change Mean change p-value ES Mean change Mean change p-value ES Mean change Mean change p-value ES Mean change Mean change p-value ES
Health    
EQ-5D-3L -0.33–1.00 + 0.00 0.00 0.670 0.02 -0.02 -0.01 0.521 0.07 -0.02 0.0 0.223 0.16 0.01 0.01 0.630 0.03
EQ-VAS 0–100 + -0.5 -0.6 0.878 0.01 -0.1 1.6 0.323 0.10 -1.7 -3.0 0.387 0.11 -0.4 -0.9 0.511 0.05
INTERMED-E-SA 0–60 - -0.1 -0.2 0.597 0.03 -1.9 -2.6 0.149 0.15 1.4 1.3 0.608 0.06 0.3 0.5 0.540 0.04
GFI 0–15 - 0.1 0.1 0.998 0.00 0.1 0.0 0.552 0.06 -0.6 -0.7 0.586 0.07 0.4 0.5 0.411 0.06
Katz-151 0–15 - 0.35 0.19 0.047 0.10 0.58 0.33 0.204 0.13 0.28 0.39 0.660 0.06 0.26 0.08 0.035 0.14
    PADL 0–6 - 0.14 0.06 0.011 0.13 0.32 0.14 0.058 0.20 0.14 0.10 0.561 0.08 0.07 0.01 0.089 0.12
    IADL2 0–7 - 0.19 0.13 0.185 0.07 0.27 0.16 0.363 0.10 0.11 0.25 0.355 0.12 0.18 0.08 0.063 0.13
Wellbeing    
GWI SF Score3 0–1 + -0.02 -0.02 0.892 0.01 -0.02 -0.03 0.512 0.07 -0.04 0.0 0.478 0.09 -0.02 -0.02 0.900 0.01
QoL general 0–5 - 0.08 0.10 0.636 0.02 0.17 0.14 0.587 0.06 0.12 0.09 0.818 0.03 0.03 0.08 0.289 0.07
QoL vs 1 year ago 0–5 - 0.08 0.04 0.320 0.05 -0.04 0.01 0.471 0.08 0.11 0.17 0.425 0.10 0.13 0.02 0.018 0.16
Self-management    
SMAS-30  0–100 + -1.1 -0.8 0.411 0.04 -2.0 0.2 0.015 0.26 -0.4 -0.7 0.705 0.05 -0.9 -1.2 0.664 0.03
    INIT 0–100 + -2.3 -2.5 0.709 0.02 -2.8 -2.1 0.530 0.07 -1.7 -2.3 0.658 0.06 -2.2 -2.8 0.485 0.05
    SE 0–100 + -0.8 -0.9 0.455 0.04 -2.1 1.7 0.020 0.24 0.0 -1.3 0.619 0.07 -0.4 -2.0 0.585 0.04
    INVEST 0–100 + -1.1 0.0 0.802 0.01 -1.3 0.8 0.005 0.30 -0.3 0.5 0.412 0.11 -1.2 -0.4 0.068 0.13
    POSITIVE 0–100 + -0.2 0.2 0.542 0.03 -0.2 1.2 0.217 0.13 -0.3 0.5 0.680 0.05 -0.1 -0.3 0.835 0.01
    MULT 0–100 + -0.8 -0.4 0.124 0.08 -1.9 1.1 0.126 0.16 -1.1 -1.7 0.609 0.07 -0.2 -0.6 0.383 0.06
    VAR 0–100 + -1.3 -0.8 0.461 0.04 -3.2 -1.3 0.177 0.14 1.2 0.3 0.450 0.10 -1.2 -0.8 0.649 0.03
PIH-OA4 8–64 + 0.8 0.4 0.285 0.06 1.1 1.1 0.976 0.00 1.7 -0.8 0.020 0.31 0.4 0.4 0.936 0.01
    Knowledge 2–16 + 0.8 0.3 0.009 0.14 0.8 0.3 0.113 0.17 1.0 -0.2 0.015 0.32 0.7 0.4 0.245 0.08
    Management 2–16 + 0.1 0.0 0.691 0.02 0.2 0.2 0.969 0.00 0.2 -0.2 0.398 0.11 -0.1 -0.1 0.965 0.00
    Coping 4–32 + 0.0 0.1 0.659 0.02 0.1 0.6 0.336 0.10 0.6 -0.4 0.119 0.21 -0.2 0.0 0.355 0.06

CAU = Care as usual; EQ-5D-3L = EuroQol-5D-3L; EQ-VAS = EuroQoL-5D visual analogue scale; ES = Effect size d, thresholds <0.2 trivial, ≥ 0.2–0.5 small, ≥0.5–0.8 medium, ≥ 0.8 large; GFI = Groningen Frailty Indicator; GWI SF Score = Groningen Well-being Indicator Satisfaction Score; IADL = Instrumental Activities of Daily Living; INIT = Taking initiatives subscale; INTERMED-E-SA = INTERMED for the Elderly Self-Assessment; INVEST = Investment behaviour subscale; MULT = Multi-functionality of resources subscale; PADL = Physical Activities of Daily Living; PIH-OA = Partners in Health scale for older adults; POSITIVE = Positive frame of mind subscale; QoL = Quality of life; SE = Self-efficacy beliefs subscale; SMAS-30 = Self-Management Ability Scale version 2; VAR = Variety in resources subscale.

* + Higher score means improvement;—higher score means deterioration.

† Values are corrected for age and sex; bold values indicate p<0.05.

1 Percentage of missing items at baseline before imputation 7.4%

2 Percentage of missing items at baseline before imputation 5.4% and 6.1% at follow-up.

3 Percentage of missing items at baseline before imputation 12.7%

4 Percentage of missing items at baseline before imputation 5.7%

Bold text and orange filling: Significant (p<0.05) or clinically relevant (ES ≥0.20) deterioration

Bold text and green filling: Significant (p<0.05) or clinically relevant (ES ≥0.20) improvement